These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12874396)

  • 21. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
    Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
    Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.
    O'Rourke KE; Hutchinson M
    Mult Scler; 2005 Feb; 11(1):46-50. PubMed ID: 15732266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-beta 1b in the treatment of multiple sclerosis.
    Río J; Montalban X
    Expert Opin Pharmacother; 2005 Dec; 6(16):2877-86. PubMed ID: 16318438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease.
    Dimitriou NG; Meuth SG; Martinez-Lapiscina EH; Albrecht P; Menge T
    CNS Drugs; 2023 Jan; 37(1):69-92. PubMed ID: 36598730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
    Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
    Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
    Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Selected issues of immunomodulating treatment in multiple sclerosis].
    Cendrowski W
    Neurol Neurochir Pol; 2004; 38(4):299-306. PubMed ID: 15383958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of a multicenter study of Rebif-22 mcg administration in Russia].
    Zavalishin IA; Gusev EI; Iakhno NN; Skoromets AA; Boĭko AN; Demina TL; Burlutskiĭ A P ; Beĭn BN; Sholomov II; Pereserdova AV; Stoĭda NI; Zakharova MN; Adarcheva LS; Niiazbekova AS; Askarova LSh; Oleĭnikov VG; Rebrova OIu; Shmidt TE; Davydovskaia MV; Totolian NA; Beskhmel'nitsina IA; Bragina OV; Ponomareva GL; Durseneva OM; Voronchikhina SA; Volkova LI; Turova EL; Streknev AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):73-8. PubMed ID: 12938639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
    Durelli L; Ferrero B; Oggero A; Verdun E; Bongioanni MR; Gentile E; Isoardo GL; Ricci A; Rota E; Bergamasco B; Durazzo M; Saracco G; Biava MA; Brossa PC; Giorda L; Pagni R; Aimo G
    J Neurol Sci; 1999 Jan; 162(1):74-83. PubMed ID: 10064173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.
    Kamm CP; El-Koussy M; Humpert S; Findling O; Burren Y; Schwegler G; Donati F; Müller M; Müller F; Slotboom J; Kappos L; Naegelin Y; Mattle HP;
    PLoS One; 2014; 9(1):e86663. PubMed ID: 24497963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
    Milanese C; La Mantia L; Palumbo R; Martinelli V; Murialdo A; Zaffaroni M; Caputo D; Capra R; Bergamaschi R;
    J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1689-92. PubMed ID: 14638892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
    van Boxel-Dezaire AH; van Trigt-Hoff SC; Killestein J; Schrijver HM; van Houwelingen JC; Polman CH; Nagelkerken L
    Ann Neurol; 2000 Sep; 48(3):313-22. PubMed ID: 10976637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis in Pakistan.
    Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S
    Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.